VOYA Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.02M Buy
87,776
+13,416
+18% +$735K ﹤0.01% 869
2026
Q1
$4.2M Sell
74,360
-33,063
-31% -$1.93M ﹤0.01% 898
2025
Q4
$6.38M Buy
107,423
+28,343
+36% +$1.54M 0.01% 778
2025
Q3
$4.28M Sell
79,080
-74,004
-48% -$4.23M ﹤0.01% 925
2025
Q2
$8.42M Buy
153,084
+52,356
+52% +$3.08M 0.01% 783
2025
Q1
$7.12M Buy
100,728
+13,109
+15% +$882K 0.01% 835
2024
Q4
$5.76M Sell
87,619
-2,726
-3% -$183K 0.01% 918
2024
Q3
$6.35M Buy
90,345
+878
+1% +$73.4K 0.01% 913
2024
Q2
$7.37M Buy
89,467
+4,534
+5% +$377K 0.01% 853
2024
Q1
$7.42M Sell
84,933
-7,829
-8% -$701K 0.01% 849
2023
Q4
$8.94M Buy
92,762
+4,662
+5% +$412K 0.01% 783
2023
Q3
$7.8M Sell
88,100
-442
-0.5% -$39.3K 0.01% 797
2023
Q2
$7.67M Buy
88,542
+7,261
+9% +$683K 0.01% 826
2023
Q1
$7.9M Buy
81,281
+4,584
+6% +$475K 0.01% 804
2022
Q4
$7.94M Buy
76,697
+3,705
+5% +$348K 0.01% 804
2022
Q3
$6.19M Buy
72,992
+48,645
+200% +$4.33M 0.01% 875
2022
Q2
$2.02M Sell
24,347
-1,245
-5% -$99.1K 0.01% 1108
2022
Q1
$1.97M Hold
25,592
﹤0.01% 1119
2021
Q4
$2.26M Sell
25,592
-3,369
-12% -$278K ﹤0.01% 1104
2021
Q3
$2.24M Sell
28,961
-126
-0.4% -$9.94K ﹤0.01% 1123
2021
Q2
$2.43M Sell
29,087
-27,560
-49% -$2.18M ﹤0.01% 1115
2021
Q1
$4.28M Sell
56,647
-576,153
-91% -$47.1M 0.01% 897
2020
Q4
$55.5M Buy
632,800
+28,662
+5% +$2.27M 0.11% 175
2020
Q3
$46M Sell
604,138
-647,917
-52% -$65.6M 0.1% 191
2020
Q2
$154M Buy
1,252,055
+397,054
+46% +$39.5M 0.36% 60
2020
Q1
$72.2M Sell
855,001
-100,274
-10% -$8.64M 0.19% 120
2019
Q4
$80.8M Buy
955,275
+159,125
+20% +$12M 0.17% 137
2019
Q3
$53.7M Sell
796,150
-27,672
-3% -$2.13M 0.12% 178
2019
Q2
$70.6M Buy
823,822
+19,570
+2% +$1.67M 0.15% 149
2019
Q1
$71.4M Sell
804,252
-28,073
-3% -$2.6M 0.16% 137
2018
Q4
$70.9M Buy
832,325
+455,754
+121% +$43.4M 0.17% 124
2018
Q3
$36.5M Buy
376,571
+36,494
+11% +$3.64M 0.08% 266
2018
Q2
$32M Sell
340,077
-15,825
-4% -$1.39M 0.07% 311
2018
Q1
$28.9M Sell
355,902
-399,609
-53% -$34.3M 0.06% 319
2017
Q4
$67.4M Sell
755,511
-40,912
-5% -$3.56M 0.14% 161
2017
Q3
$74.1M Buy
796,423
+101,595
+15% +$8.98M 0.16% 140
2017
Q2
$63.1M Buy
694,828
+43,029
+7% +$3.91M 0.14% 161
2017
Q1
$57.2M Buy
651,799
+49,170
+8% +$4.37M 0.13% 158
2016
Q4
$49.9M Sell
602,629
-12,709
-2% -$1.09M 0.12% 172
2016
Q3
$56.9K Sell
615,338
-10,009
-2% -$943K 0.11% 159
2016
Q2
$48.7M Buy
625,347
+145,907
+30% +$12.4M 0.12% 168
2016
Q1
$39.5M Sell
479,440
-6,560
-1% -$534K 0.1% 195
2015
Q4
$50.9M Sell
486,000
-114,138
-19% -$11.9M 0.12% 167
2015
Q3
$63.2M Sell
600,138
-26,316
-4% -$3.52M 0.16% 139
2015
Q2
$85.7M Sell
626,454
-13,107
-2% -$1.62M 0.2% 120
2015
Q1
$79.7M Buy
639,561
+569,545
+813% +$60.3M 0.18% 127
2014
Q4
$6.33M Sell
70,016
-3,753
-5% -$312K 0.01% 732
2014
Q3
$5.32M Sell
73,769
-726
-1% -$47.7K 0.01% 777
2014
Q2
$4.63M Sell
74,495
-9,128
-11% -$551K 0.01% 847
2014
Q1
$5.7M Buy
83,623
+90
+0.1% +$6.63K 0.01% 770
2013
Q4
$5.87M Sell
83,533
-1,956
-2% -$133K 0.01% 754
2013
Q3
$6.17M Sell
85,489
-369
-0.4% -$24.5K 0.02% 718
2013
Q2
$4.79M Buy
+85,858
New +$5.35M 0.01% 786

Other funds holding BMRN

VOYA Investment Management's BMRN Position: Q2 2026 in Review

VOYA Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 18% in Q2 2026, buying an estimated $735K and bringing the position to 87,776 shares worth $5.02M. The position accounts for ﹤0.01% of the portfolio, ranked #869.

VOYA Investment Management first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $154M in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • VOYA Investment Management held 87,776 shares of BioMarin Pharmaceuticals worth $5.02M as of Q2 2026.
  • VOYA Investment Management bought 13,416 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $735K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #869 holding.
  • VOYA Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • VOYA Investment Management's BioMarin Pharmaceuticals position peaked at $154M in Q2 2020.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.